Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Pancreatic Incidentaloma: Take it or Leave it ?

  • Received : 2016.11.28
  • Accepted : 2016.12.23
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Udelsman R, Fishman EK. Radiology of the adrenal. Endocrinol Metab Clin North Am 2000;29:27-42.
  2. Thompson GB, Young WF Jr. Adrenal incidentaloma. Curr Opin Oncol 2003;15:84-90.
  3. Kostiuk TS. Observation of pancreatic incidentaloma. Klin Khir 2001;9:62-63.
  4. Fernandez-del Castillo C, Targarona J, Thayer SP, et al. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003;138:427-423; discussion 433-434.
  5. Handrich SJ, Hough DM, Fletcher JG, et al. The natural history of the incidentally discovered small simple pancreatic cyst: long- term follow-up and clinical implications. AJR Am J Roentgenol 2005;184:20-23.
  6. Winter JM, Cameron JL, Lillemoe KD, et al. Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. Ann Surg 2006;243:673-683.
  7. Sachs T, Pratt WB, Callery MP, Vollmer CM Jr. The Incidental Asymptomatic Pancreatic Lesion: Nuisance or Threat? J Gastrointest Surg 2009;13:405-415.
  8. Lahat G, Haim MB, Nachmany I, et al. Pancreatic Incidentalomas: High Rate of Potentially Malignant Tumors. J Am Coll Surg 2009;209:313-319.
  9. Karatzas T, Dimitroulis D, Charalampoudis P, et al. Management of cystic and solid pancreatic incidentalomas: A review analysis. J Buon 2013;18(1):17-24.
  10. Herrera MF, Akerstrom G, Angelos P, et al. AACE/ACE Disease State Clinical Review: Pancreatic Neuroendocrine Incidentalomas. Endocr Pract 2015;21(5):546-553.
  11. Kent TS, Vollmer Jr CM, Callery MP. Intraductal papillary mucinous neoplasm and the pancreatic incidentaloma. World J Gastrointest Surg 2010;27:319-323.
  12. Fong ZV, Winter JM. Biomarkers in Pancreatic Cancer: Diagnostic, Prognostic, and Predictive. Cancer J 2012;18:530-538.
  13. Maithel SK, Maloney S, Winston C, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 2008;15:3512-3520.
  14. van den Bosch RP, van Eijck CH, Mulder PG, et al. Serum CA 19-9 determination in the management of pancreatic cancer. Hepatogastroenterology 1996;43:710-713.
  15. Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010;39:713-734.
  16. Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95:120-134.
  17. Nobels FR, Kwekkeboom DJ, Bouillon R, et al. Chromogranin A: Its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998;28:431-440.
  18. Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia: An Italian Multicenter Study. Endocr Relat Cancer 2007;14:473-482.
  19. Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732-738.
  20. Frulloni L, Lunardi C, Simone R, et al. Identification of a Novel Antibody Associated with Autoimmune Pancreatitis. N Engl J Med 2009;361:2135-2142.
  21. Morselli-Labate AM, Pezzilli R. Usefulness of serum IgG4 in the diagnosis and follow up of autoimmune pancreatitis: A systematic literature review and meta-analysis. J Gastroenterol Hepatol 2009;24:15-36.
  22. Liang JJ, Kimchi ET, Staveley-O'Carroll KF, et al. Diagnostic and prognostic biomarkers in pancreatic carcinoma. Int J Clin Exp Pathol 2009;2:1-10.
  23. Torphy RJ, Tignanelli CJ, Kamande JW, et al. Circulating Tumor Cells as a Biomarker of Response to treatment in Patient-Derived Xenograft Mouse Models of Pancreatic Adenocarcino ma, Plos One 2014;9(2):e89474.
  24. Jones S, Zhang X, Parsons DW, et al. Core Signaling pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Sciences 2008;321(5897):1801-1806.
  25. Liu R, Chen X, Du Y, et al. Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer. Clin Chem 2012;58:610-618.
  26. Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010;70(11):4528-4538.
  27. Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: A state-of-the-art review. World J Gastroenterol 2014;20(24):7864-7877.
  28. Yoon SH, Lee JM, Cho JY, et al. Small (20 mm) pancreatic adenocarcinomas: Analysis of enhancement patterns and secondary signs with multiphasic multidetector CT. Radiology 259:442-452.
  29. Griffin N, Charles-Edwards G, Grant LA. Magnetic resonance cholangiography: the ABC of MRCP, European Society of Radiology. Insights Imaging 2012;3:11-21.
  30. Dutta AK, Chacko A. Head mass in chronic pancreatitis: Inflam matory or malignant. World J Gastroenterol Endosc 2015;7(3):258-264.
  31. Nagamachi S, Nishii R, Wakamatsu H, et al. The usefulness of 18F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with 18F-FDG PET/CT. Ann Nucl Med 2013;27:554-563.
  32. Wiersema MJ.Accuracy of endoscopic ultrasound in diagnosing and staging pancreatic carcinoma. Pancreatology 2001;1:625-632.
  33. Yamao K, Sawaki K, Mizuno N, et al. Endoscopic Ultrasound-guided fine-needle aspiration biopsy (EUS-FNAB); past, present, and future. J Gastroenterol 2005;40:1013-1023.
  34. Bournet B, Sonque A, Senesse P, et al. Endoscopic ultrasoundguided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. Endoscopy 2009;41:552-557.
  35. Bournet B, Gayral M, Torrisani J, et al. Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer. World J Gastroenterology 2014;20(31):10758-10768.
  36. Jang SI, Lee DK. Contrast-enhanced endoscopic ultrasonography: advance and current status. Ultrasonography 2014;33:161-169.
  37. Arcidiacono PG. Advances in endoscopy: Current development in diagnostic and therapeutic endoscopy. Endoscopy 2012;8(1):48-67.
  38. Rockacy M, Khalid A.Update on pancreatic cyst fluid analysis. Ann Gastroenterol 2013;26(2):122-127.
  39. Khalid A, Zahid M, Finkelstein SD, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 2009;69:1095-1102.
  40. Bruzoni M, Johnston E, Sasson AR. Pancreatic incidentalomas: clinical and pathologic spectrum. Am J Surg 2008;195:329-332.
  41. Franco J, Feng W, Yip L, et al. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology and outcomes in 2,158 patients. J Gastrointest Surg 2010;14:541-548.
  42. Boninsegna L, Partelli S, D'Innocenzio MM, et al. Pancreatic cystic neuroendocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology 2010;92:246-251.
  43. Conrad C, Fernandez-del Castillo C. Preoperative evaluation and management of the pancreatic head mass. J Surg Oncol 2013;107:23-32.
  44. Sarr MG, Murr M, Smyrk TC, et al. Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions. J Gastrointest Surg 2003;7:417-428.
  45. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183-197.